ReviewJournal of medicinal chemistry2014
The current state of drug discovery and a potential role for NMR metabolomics.
Review in Journal of medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Protocols for Metabolomic Analyses to Assess Changes in Central Carbon Metabolism from Neural Tissue.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Simulated LC-MS Data Set for Assessing the Metabolomics Data Processing Pipeline Implemented into MVAPACK.Analytical chemistry · 2024Article
- Best Practices in NMR Metabolomics: Current State.Trends in analytical chemistry : TRAC · 2024Article
- Multiplatform untargeted metabolomics.Magnetic resonance in chemistry : MRC · 2023Review
- Effects of Solvent Evaporation Methods and Short-Term Room Temperature Storage on High-Coverage Cellular Metabolome Analysis.Metabolites · 2023Article
- Demographic, Health and Lifestyle Factors Associated with the Metabolome in Older Women.Metabolites · 2023Article
- Deciphering the mechanism of action of antitubercular compounds with metabolomics.Computational and structural biotechnology journal · 2021Review
- Nuclear Magnetic Resonance Spectroscopy in Clinical Metabolomics and Personalized Medicine: Current Challenges and Perspectives.Frontiers in molecular biosciences · 2021Review
- Metabolomic study of soft corals from the Colombian Caribbean: PSYCHE andScientific reports · 2020Article
- NMR Metabolomics Protocols for Drug Discovery.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Metabolomics Analyses from Tissues in Parkinson's Disease.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Combining Mass Spectrometry and NMR Improves Metabolite Detection and Annotation.Journal of proteome research · 2018Article
- Application of metabolomics to drug discovery and understanding the mechanisms of action of medicinal plants with anti-tuberculosis activity.Clinical and translational medicine · 2018Review
- Expanding the Coverage of the Metabolome with Nitrogen-Based NMR.Analytical chemistry · 2018Article
- A Novel Anti-Hepatitis C Virus and Antiproliferative Agent Alters Metabolic Networks in HepG2 and Hep3B Cells.Metabolites · 2017Article
- Whole Blood Metabolomics byAnalytical chemistry · 2017Article
- The future of NMR-based metabolomics.Current opinion in biotechnology · 2017Review
- Recent Advances in NMR-Based Metabolomics.Analytical chemistry · 2017Review
- Metabolomics: Bridging the Gap between Pharmaceutical Development and Population Health.Metabolites · 2016Review
- Protection of baicalin against lipopolysaccharide induced liver and kidney injuries based onToxicology research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The pharmaceutical industry has significantly contributed to improving human health. Drugs have been attributed to both increasing life expectancy and decreasing health care costs. Unfortunately, there has been a recent decline in the creativity and productivity of the pharmaceutical industry. This is a complex issue with many contributing factors resulting from the numerous mergers, increase in out-sourcing, and the heavy dependency on high-throughput screening (HTS). While a simple solution to such a complex problem is unrealistic and highly unlikely, the inclusion of metabolomics as a routine component of the drug discovery process may provide some solutions to these problems. Specifically, as the binding affinity of a chemical lead is evolved during the iterative structure-based drug design process, metabolomics can provide feedback on the selectivity and the in vivo mechanism of action. Similarly, metabolomics can be used to evaluate and validate HTS leads. In effect, metabolomics can be used to eliminate compounds with potential efficacy and side effect problems while prioritizing well-behaved leads with druglike characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.